![Sylvain Celanire](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Sylvain Celanire
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Augustine Therapeutics NV
![]() Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.
6
| Holding Company | Medical/Nursing Services | 6 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Sylvain Celanire via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Katholieke Universiteit Leuven | College/University | Doctorate Degree Doctorate Degree | |
NEOVACS | Pharmaceuticals: Major | President | |
Candriam Belgium SA
![]() Candriam Belgium SA Investment ManagersFinance Candriam Belgium SA (Candriam) is the Belgian asset management subsidiary of Candriam Luxembourg SCA, ultimately held by New York Life Insurance Co. in the US. Founded in 1998, the firm was formerly known as Dexia Asset Management Belgium SA, the asset management division of Dexia SA (XB: DEXB). In 2014, New York Life Investments acquired Dexia Asset Management and the firm changed their name to Candriam, which is an acronym of their core values: “Conviction and Responsibility in Asset Management”. Headquartered in Brussels, Candriam provides discretionary and non-discretionary investment advisory services to US registered funds, a limited number of US natural persons, and to institutions. | Investment Managers | Analyst-Equity | |
Aelin Therapeutics NV
![]() Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member | |
Participatiemaatschappij Vlaanderen NV
![]() Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investment Managers | Private Equity Investor | |
Waaroost NV | Director/Board Member | ||
Exevir Bio BV
![]() Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Pulsify Medical BV
![]() Pulsify Medical BV Medical SpecialtiesHealth Technology Pulsify Medical BV is a Belgian digital medical technology company that specializes in developing wearable ultrasound patches. The company is based in Louvain, Belgium. Pulsify Medical was founded in 2019 by Lieven Herbots, Xavier Rottenberg, Jan D'hooge, Steve Stoffels. Iwan van Vijfeijken has been the CEO of the company since 2019. | Medical Specialties | Director/Board Member | |
V-Bio Ventures BV
![]() V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Investment Managers | Private Equity Investor | |
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member | |
DiogenX SAS
![]() DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Biotechnology | Director/Board Member | |
Urania Therapeutics SAS
![]() Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Biotechnology | Chairman | |
Alderaan Biotechnology SAS
![]() Alderaan Biotechnology SAS BiotechnologyHealth Technology Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
AdBio Partners SAS
![]() AdBio Partners SAS Investment ManagersFinance AdBio Partners SAS (AdBio Partners) is a venture capital firm founded in 2015. The firm is headquartered in Paris, France. | Investment Managers | Founder | |
Orphalan SA
![]() Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman | |
Luxfold S.A.
![]() Luxfold S.A. BiotechnologyHealth Technology Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg. | Biotechnology | Founder | |
Advent Venture Partners LLP
![]() Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Tc Land Expression SA
![]() Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Miscellaneous Commercial Services | Founder | |
AstriVax NV
![]() AstriVax NV BiotechnologyHealth Technology AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
België | 10 |
Frankrijk | 10 |
Luxemburg | 2 |
Verenigd Koninkrijk | 2 |
Sectoraal
Health Technology | 11 |
Finance | 6 |
Consumer Services | 3 |
Commercial Services | 3 |
Operationeel
Director/Board Member | 14 |
Chairman | 4 |
Private Equity Investor | 4 |
President | 3 |
Founder | 3 |
Sterkste connecties
Insiders | |
---|---|
Alain Huriez | 12 |
Bart De Taeye | 5 |
Ward Capoen | 3 |
Jérôme van Biervliet | 3 |
Bart Geers | 2 |
Erik Tambuyzer | 2 |
- Beurs
- Insiders
- Sylvain Celanire
- Bedrijfsconnecties